Please try another search
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Name | Age | Since | Title |
---|---|---|---|
Daniel J. Wallace | - | - | Member of Clinical Advisory Board |
Osnat Hillel Fain | 55 | 2015 | Independent Non-Executive & External Director |
Murray Urowitz | - | - | Member of Clinical Advisory Board |
Robert I. Fox | - | 2017 | Member of Clinical Advisory Board |
Lee S. Simon | 70 | - | Member of Clinical Advisory Board |
Simon Bowman | - | 2017 | Member of Clinical Advisory Board |
David Isenberg | - | 2015 | Member of Clinical Advisory Board |
Jonathan Schapiro | 61 | 2014 | Non-Executive Director |
Shlomo Spokone Shalev | 59 | 2014 | CEO & Director |
Doron Turgeman | 53 | 2014 | Non-Executive Chairman of the Board |
Alexander Rabinovich | 51 | 2017 | Non-Executive Director |
Dobroslav Melamed | 46 | 2014 | Independent Non-Executive Director |
Iris Shapira Yalon | 56 | 2020 | Independent Non-Executive & External Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review